Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Comparative summary of chromatographic methods developed for S -(−)-metoprolol and R -(+)-metoprolol in biological matrices.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques: Sample Prep, Binding Assay, Dried Blood Spots Assay, Plasma Assay

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Product ion mass spectra of: (A) S -(−)-metoprolol ( m/z 268.3→116.3, scan range 100–300 amu), (B) R -(+)-metoprolol ( m/z 268.3→116.3, scan range 100–300 amu), and (C) Rac -metoprolol-d6, internal standard ( m/z 274.2→122.2, scan range 100–300 amu) in positive ionization mode.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Mean relative recovery and absolute matrix effect of S -(−)-metoprolol and R -(+)-metoprolol by LLE and SPE at LQC level.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Chromatograms of metoprolol enantiomers ( m/z 268.3→116.3) obtained on: (A) protein based Chiral-AGP (250 mm×4.6 mm, 5 μm), ( S ), (B) Chiralcel ® OD (250 mm×4.6 mm, 5 μm) and (C) Lux Amylose-2 (250 mm×4.6 mm, 5 μm). Mobile phase for column (A) 15 mM ammonium acetate, pH 5.0 adjusted with acetic acid-0.1% diethyl amine in acetonitrile (70:30, v/v), for (B) and (C) 15 mM ammonium acetate, pH 5.0 adjusted with acetic acid-0.1% diethyl amine in acetonitrile (50:50, v/v).

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: MRM ion-chromatograms of: (A) double blank plasma (without IS), (B) blank plasma with rac -metoprolol-d6 (IS), (C) S -(−)-metoprolol and R -(+)-metoprolol at LLOQ level ( m/z 268.3→116.3) and IS ( m/z 274.2→122.2), and (D) real subject sample at 5.0 h after administration of 200 mg extended release metoprolol tablet.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Post-column analyte infusion MRM LC–MS/MS chromatograms for: (A) S -(−)-metoprolol and R -(+)-metoprolol ( m/z 268.3→116.3), and (B) Rac -metoprolol-d6 ( m/z 274.2→122.2).

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques: Liquid Chromatography with Mass Spectroscopy

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: MRM ion-chromatograms for carry-over test of: (A) double blank plasma (without analyte and IS), (B) S -(−)-metoprolol and R -(+)-metoprolol at ULOQ level and IS, (C) double blank plasma (without analyte and IS) and (D) S -(−)-metoprolol and R -(+)-metoprolol at LLOQ level and IS.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Intra-batch & inter-batch accuracy and precision for S -(−)-metoprolol and R -(+)-metoprolol.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques: Concentration Assay

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Absolute matrix effect, relative recovery and process efficiency for S -(−)-metoprolol and R -(+)-metoprolol.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Relative matrix effect in different human plasma lots for S -(−)-metoprolol and R -(+)-metoprolol.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Stability results for S -(−)-metoprolol and R -(+)-metoprolol under different conditions ( n =6).

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Mean plasma concentration-time profile of: (A) S -(−)-metoprolol and (B) R -(+)-metoprolol after oral administration of test (200 mg metoprolol succinate extended release tablet from an Indian Pharmaceutical Company, India) and reference (Selo-zok ® , 200 mg metoprolol succinate extended release tablet from AstraZeneca, Denmark) formulations to 14 healthy Indian subjects under fasting conditions.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques: Concentration Assay

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Mean pharmacokinetic parameters of S -(−)-metoprolol and R -(+)-metoprolol (Mean±SD).

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Comparison of treatment ratios and 90% CIs of natural log (Ln)-transformed parameters for S -(−)-metoprolol and R -(+)-metoprolol under fasting condition.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: Journal of Pharmaceutical Analysis

Article Title: Development of a sensitive and rapid method for quantitation of ( S )-(−)- and ( R )-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS

doi: 10.1016/j.jpha.2013.02.008

Figure Lengend Snippet: Graphical representation of results for 68 incurred samples of S -(−)-metoprolol and R -(+)- metoprolol.

Article Snippet: Reference standards of S -(−)-metoprolol (99.0%) and R -(+)-metoprolol (99.0%) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada), while rac -metoprolol-d6 (99.6%) used as an internal standard (IS) was from TLC Pharmachem Inc. (Ontario, Canada).

Techniques:

Journal: PLOS ONE

Article Title: Ginseng Radix et Rhizoma enhanced the effect of metoprolol in chronic heart failure by inhibiting autophagy in male C57BL/6J mice

doi: 10.1371/journal.pone.0301875

Figure Lengend Snippet: Typical echocardiograms (A), left ventricular ejection fraction (EF%) (B), left ventricular fractional shortening (FS%), left ventricular internal diameter at diastole (LVID,d) (D), left ventricular internal diameter at systole (LVID,s) (E), interventricular septum thickness at diastole (IVS,d) (F), and interventricular septum thickness at systole (IVS,s) (G) of heart failure mice treated with GS combined with metoprolol (Met). Data are represented as mean ± SEM (n = 7–10). #p < 0.05 or ##p < 0.01 vs. sham. *p < 0.05 or ** p < 0.01 vs. model. & p < 0.05 vs. 2.6g/kg GS or 6.25mg/kg Met.

Article Snippet: Metoprolol tartrate tablets (H32025391) were obtained from MedChemExpress. (Shanghai, China).

Techniques:

Journal: bioRxiv

Article Title: Nutrient availability dictates cancer metabolism-based therapeutic responses of non-oncology drugs

doi: 10.1101/2025.01.05.631340

Figure Lengend Snippet: a Dot plot of FDA-approved oncology drugs from the CM-SLP glu screen showing relative cell viability under high glucose (x-axis) versus low glucose (y-axis). Procainamide, quinidine, lidocaine, phenytoin, sotalol, diltiazem, propranolol, metoprolol (quadrant 1, black), amiodarone (quadrant 3, blue), propafenone (quadrant 4, red), and verapamil (quadrant 4, orange) are marked. b Schematic graph of anti-arrhythmic drugs affecting cardiac action potentials. c Representative traces of normalized whole-cell K + currents in the presence of the indicated drugs. Intracellular Ca 2+ was fixed at 1 μM, and all drugs were added to the extracellular side. Drugs were used at the following concentrations: flecainide, 20 μM; procainamide, 20 μM; quinidine, 20 μM; lidocaine, 20 μM; phenytoin, 20 μM; sotalol, 20 μM; diltiazem, 20 μM; propranolol, 20 μM; and metoprolol, 20 μM. d Normalized currents and voltage-current relationships for whole-cell K + currents in the presence of the indicated drugs. Normalized currents at 100 mV in the presence of amiodarone, 0.481 ± 0.033 (n = 8); flecainide, 0.962 ± 0.014 (n = 8); procainamide, 1.002 ± 0.023 (n = 10); quinidine, 0.877 ± 0.053 (n = 8); lidocaine, 1.030 ± 0.024 (n = 8); phenytoin, 0.976 ± 0.045 (n = 8); sotalol, 1.015 ± 0.011 (n = 8); diltiazem, 1.019 ± 0.021 (n = 10); propranolol, 0.966 ± 0.027 (n = 8); and metoprolol, 0.960 ± 0.020 (n = 9). In c and d, the currents were evoked by −90 mV pre-pulse for 50 ms, then −90 to 100 mV test pulses for 200 ms with 10-mV increments, and then −90 mV post-pulse for 50 ms. The channel activity was calculated as the average current density during the last 50 ms of each test pulse.

Article Snippet: Tram-34 (S1160), tetraethylammonium chloride (S4489), propranolol hydrochloride (S4076), metoprolol (S5430), and temsirolimus (S1044) were purchased from Selleckchem.

Techniques: Activity Assay

Journal: bioRxiv

Article Title: Nutrient availability dictates cancer metabolism-based therapeutic responses of non-oncology drugs

doi: 10.1101/2025.01.05.631340

Figure Lengend Snippet: a Viability of 786-O cells subjected to amiodarone (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). b Viability of 786-O cells subjected to flecainide (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). c Viability of 786-O cells subjected to procainamide (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). d Viability of 786-O cells subjected to quinidine (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). e Viability of 786-O cells subjected to lidocaine (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). f Viability of 786-O cells subjected to phenytoin (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). g Viability of 786-O cells subjected to sotalol (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). h Viability of 786-O cells subjected to diltiazem (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). i Viability of 786-O cells subjected to propranolol (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). j Viability of 786-O cells subjected to metoprolol (0, 10, 30 μM, 48 h) treatment in the presence of high glucose (25 mM), low glucose (1 mM), or the GLUT inhibitor BAY-876 (3 μM). k-t Immunoblotting analysis of cancer-related signaling pathways in cells treated with the indicated drugs (0, 10, 30 μM, 8 h) in the presence of either high (25 mM) or low (1 mM) glucose. -, negative control; low dose, 10 μM; high dose, 30 μM.

Article Snippet: Tram-34 (S1160), tetraethylammonium chloride (S4489), propranolol hydrochloride (S4076), metoprolol (S5430), and temsirolimus (S1044) were purchased from Selleckchem.

Techniques: Western Blot, Negative Control

Journal: Molecules

Article Title: In Vitro Metabolic Transformation of Pharmaceuticals by Hepatic S9 Fractions from Common Carp (Cyprinus carpio)

doi: 10.3390/molecules25112690

Figure Lengend Snippet: Concentrations of metabolites formed under the tested conditions.

Article Snippet: Citalopram, sertraline, and venlafaxine were purchased from AK Scientific (Union City, NJ, USA); metoprolol and tris( n -butyl) phosphate (TNBP) from Sigma Aldrich (Darmstadt, Germany); metabolites norsertraline and N -desmethylcitalopram from Labicom (Olomouc, The Czech Republic); metoprolol acid from Toronto Research Chemicals and O -desmethylvenlafaxine; and chemicals for preparation of S9 fractions and performing biochemical reactions from Sigma Aldrich (Darmstadt, Germany).

Techniques: Concentration Assay, Control

Journal: Molecules

Article Title: In Vitro Metabolic Transformation of Pharmaceuticals by Hepatic S9 Fractions from Common Carp (Cyprinus carpio)

doi: 10.3390/molecules25112690

Figure Lengend Snippet: Incubation procedure of piscine or ovine S9 fractions to study formation of major metabolites of selected pharmaceuticals.

Article Snippet: Citalopram, sertraline, and venlafaxine were purchased from AK Scientific (Union City, NJ, USA); metoprolol and tris( n -butyl) phosphate (TNBP) from Sigma Aldrich (Darmstadt, Germany); metabolites norsertraline and N -desmethylcitalopram from Labicom (Olomouc, The Czech Republic); metoprolol acid from Toronto Research Chemicals and O -desmethylvenlafaxine; and chemicals for preparation of S9 fractions and performing biochemical reactions from Sigma Aldrich (Darmstadt, Germany).

Techniques: Incubation, Concentration Assay, Control